This finding was also applied to humans, María Inés Barría, a microbiologist and coordinator of this research, said EFE started in 2014, and its first conclusions were published in Science Translational Medicine.
The Hanta virus is an infection, transmitted by the rodent to people, and the Andean subtypes, which affect the areas of Chile and Argentina in Patagonia, are the only ones that can be spread among people.
Andes hantavirus infection is a very dangerous condition known as Hantavirus Cardiopulmonary Syndrome (SCPH), which causes fever, headache, low blood pressure and heart and lung failure. mortality rates
The results of the study showed that survivors' antibodies were protected by animals suffering from SCPH following the hantavirus infection in the Andes.
This suggests that nowadays it can be used as a preventive treatment for postoperative illnesses, according to research.
"Until now, there is no specific treatment for this infection, the only thing that can be done by the doctor is the UTI treatment," said Barria.
In 2017, 90 people were infected with the Andean hantavirus, of which 24 SCPH were killed.
There are groups that work in emergencies or work in agricultural or forest areas and are more influential in young people to deal with this infection.
Method of study method The isolation of the antibodies against 27 patients with survival of the sore hantavirus or a more symptomatic symptomatology.
The next step was injected by the hamster with the deadly dosage of the virus and then gave them human antibodies, and all of them were prevented and survived.
"Because Hamsters were a model that resembles the symptoms and symptoms of human beings," Barria explained.
Currently, the University of Concepción develops a dose of appropriate people and, in this way, to be tested in a clinical trial, there are also effects of isolated antibodies that have been successful in rodents.
Also, after testing, this method prevents the development of SCES once Andes hantavirus is infected, scientists want to study mice to prevent the infection of this virus.
"As our idea is a profilactic animal, in order to manage the doses before the infection, we will increase the spectrum of these antibodies", added Barril to find a substance that prevents the infection.
According to experts, it could be a "short term vaccine", which antibodies "would protect people in the short term".
"Even if the protection lasts for three weeks or two, risk groups would also be useful: forest workers, agricultural workers, tourists to Patagonia or even to face a great splendor," he added.
The researcher also stated that this discovery could be a cure for other European and Asian types.
"The problem is not the technology, the desire or the ideas, but the financing we need is to know the extent to which it is," said Barril.